• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Drugs in Development

To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. 

For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.

Clinical Trial Information

Here are links to databases of known clinical trials for ALS/MND.

  • ALS/MND Clinical Trial Navigator: The ALS Therapy Development Institute created the ALS Trial Navigator is a comprehensive resource for making informed decisions about participating in ALS/MND clinical trials. Use this innovative tool learn about clinical trials and get a personalized list of ALS/MND trials based on your eligibility and preferences. (Language: English)
  • ALS International Clinical Trial Database: The Associazione conSLAncio Onlus created the ALS/MND International Clinical Trial Database. Built on a multi-lingual website, this features users to view the current status of clinical trials taking place at sites in, or close to, Italy. Each trial is linked to the official trial registry where users can directly access study objectives, eligibility criteria and study contacts. (Language: Italian)
  • HEALEY ALS Platform Trial: The HEALEY ALS Platform Trial aims to accelerate the process of drug development and the path for effective treatment for ALS/MND by testing multiple drugs simultaneously and adaptively. This design has been seen to be successful in cancer trials. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to receive either the study drug or placebo. New regimens will be continuously added as new investigational products become available. The trial is recruiting in the United States only and will enroll additional participants as each new regimen is available. (Language: English)

Information on Drugs in Clinical Trial

Here are briefing notes from the International Alliance’s Scientific Advisory Council on drugs and therapies currently being researched.

SPG302

Masitinib

Pridopidine

NP001

Neuronata-R / Lenzumestrocel

Ulefnersen

NurOwn

CNM-Au8

AstroRx

ILB

PrimeC

SOD1-Targeted Therapies & Trials

Regulatory T Cell Enhancing Therapies

C9orf72 Therapies and Trials

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Andrew Langat, Kenya

    Andrew Langat, Kenya

  • Jon Newsome, USA

    Jon Newsome, USA

  • Animesh Kumar, India

    Animesh Kumar, India

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • David Bishop, UK

    David Bishop, UK

  • Lee Millard, England

    Lee Millard, England

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Hollister

    Hollister
    hollister

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Steve

    Steve

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Zabun Nassar, England

    Zabun Nassar, England

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Bayley, Australia

    Bayley, Australia

  • JP

    JP

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Dick Dayton, USA

    Dick Dayton, USA

  • Jan Zuring, Netherlands

    Jan Zuring, Netherlands

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Anna Barrow, UK

    Anna Barrow, UK

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login